Vaxcyte, Inc.
NEWS
The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like Merck and Pfizer.
As Vaxcyte targets it’s the pneumococcal vaccine market, the company is facing significant competition from major pharma companies already in the space.
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
In a stunning fall from grace playing out this week, former Operation Warp Speed vaccine czar, Dr. Moncef Slaoui, issued a statement Thursday morning, as news emerged that he has resigned from additional biotech posts.
The company’s lead vaccine candidate, SVX-24, is a preclinical, 24-valent pneumococcal conjugate vaccine.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
JOBS
IN THE PRESS